Exicure, Inc.
XCURHealthcare|Biotechnology|US
$0.95
+0.06 (+6.71%)
DCF Value
$0.35
Cash / Share
$0.27
About
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Stock Price
-77.7%(1Y)
1M
-5.0%
3M
-29.6%
6M
-71.8%
YTD
-82.5%
1Y
-75.5%
3Y
-69.0%
5Y
-99.4%
Pipeline Summary
2 total trials2
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Completed: 1Terminated: 1
Key Facts
Market Cap$6.2M
Employees8 (+14% YoY)
CEOJungsoo Kim
IPO DateMay 22, 2018
Beta3.74
52-Week Range$0.856 – $9.48
Avg Volume402,530
ExchangeNASDAQ
Websiteexicuretx.com
Ownership
Float28.1%
Shares Outstanding6.5M
Recent Insider Trades
Exicure HiTron Inc.J
Jul 8, 2026117,441 shares @ $4.50
Exicure HiTron Inc.J
Jun 26, 2026253,195 shares @ $4.50
Exicure HiTron Inc.J
Jun 24, 2026123,456 shares @ $4.50
Exicure HiTron Inc.J
Jun 23, 2026129,183 shares @ $4.50
Miller JoshTAX W/H
Feb 16, 20268 shares @ $4.08
Peers
Recent News
Comparing Shattuck Labs (NASDAQ:STTK) & Exicure (NASDAQ:XCUR)
Oct 16, 2026 · defenseworld.net
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement
Sep 16, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:40 AM